Clinical TrialApr 21, 2026, 05:37 PM
Revolution Medicines' Daraxonrasib Shows 58% ORR in Pancreatic Cancer
AI Summary
Revolution Medicines announced updated Phase 1/2 clinical data for daraxonrasib in previously untreated metastatic pancreatic cancer, showing promising results for both monotherapy and combination with chemotherapy. The daraxonrasib plus gemcitabine and nab-paclitaxel (GnP) combination achieved a 58% objective response rate and 84% 6-month progression-free survival in 40 patients. The data supports continued evaluation in the first-line setting, including the ongoing Phase 3 RASolute 303 trial, indicating potential for a novel RAS-targeted therapy.
Key Highlights
- Daraxonrasib + GnP showed 58% ORR in 40 metastatic PDAC patients.
- 6-month progression-free survival was 84%; 6-month overall survival was 90%.
- Manageable safety profile; 5% daraxonrasib discontinuation.
- Data supports continued evaluation in ongoing Phase 3 RASolute 303 trial.